Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2019-04-23
DOI
10.1080/13696998.2019.1609485
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of costs associated with adverse events in patients with cancer
- (2018) William Wong et al. PLoS One
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
- (2017) Luis Silva Miguel et al. VALUE IN HEALTH
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Challenging the standard of care in advanced melanoma: focus on pembrolizumab
- (2017) Raghad Abdul-Karim et al. Cancer Management and Research
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- (2016) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Pembrolizumab for Unresectable Metastatic Melanoma After Progression with Ipilimumab in England
- (2015) E Marriott et al. VALUE IN HEALTH
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma
- (2012) T. M. Herndon et al. ONCOLOGIST
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Health Care Costs for Patients With Cancer at the End of Life
- (2012) Benjamin Chastek et al. Journal of Oncology Practice
- Economic Burden of Melanoma in the Elderly Population
- (2010) Anne M. Seidler et al. ARCHIVES OF DERMATOLOGY
- Societal preference values for advanced melanoma health states in the United Kingdom and Australia
- (2009) K M Beusterien et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started